More on Teva (TEVA +0.1%) Q2: net profit rises to $863M from $576M, due to the launch of four...


More on Teva (TEVA +0.1%) Q2: net profit rises to $863M from $576M, due to the launch of four new generic drugs in the U.S. and an increase in sales of branded treatments. Affirms FY outlook for adjusted EPS of $5.30-$5.40 vs. consensus of $5.37 and revenue of $20-$21B vs. $20.58B. U.S. sales +28% to $2.5B, European sales unchanged at $1.5B.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs